Company News: Page (1) of 1 - 02/15/13 Email this story to a friend. email article Print this page (Article printing at MyDmn.com).print page facebook

Curis to Present at Upcoming Investor Conferences

(February 15, 2013)

LEXINGTON, Mass., Feb. 15, 2013 (GLOBE NEWSWIRE) -- Curis, Inc. (Nasdaq:CRIS), an oncology-focused company seeking to develop next generation targeted drug candidates for cancer treatment, today announced that the Company will be presenting at the following upcoming conferences in New York City:




  • Citi 2013 Global Healthcare Conference – Monday, February 25, 2013 at 3 p.m. EST. A corresponding audio webcast of this presentation can be accessed by visiting:




http://www.veracast.com/webcasts/citigroup/healthcare2013/48110523.cfm





  • RBC Capital Markets 2013 Healthcare Conference - Tuesday, February 26, 2013 at 2:05 p.m. A corresponding audio webcast of this presentation can be accessed by visiting:




http://www.veracast.com/webcasts/rbc/healthcare2013/32111248.cfm



The presentations are scheduled to take place in a fireside chat format in which Daniel Passeri, President and Chief Executive Officer, will provide a brief overview of the Company's business strategy and pipeline of small molecule targeted cancer drug candidates, after which an equity analyst will moderate a question and answer session.




The audio webcasts will be archived shortly after the live events and available for 30 days following the conference.



About Curis, Inc.



Curis is an oncology-focused drug development company seeking to develop and commercialize next generation targeted small molecule drug candidates for cancer treatment. Erivedge® is the first and only FDA-approved medicine for the treatment of advanced basal cell carcinoma and is being commercialized and developed by Roche and Genentech, a member of the Roche Group, under a collaboration agreement between Curis and Genentech. Curis is also leveraging its experience in targeting signaling pathways to develop proprietary targeted cancer programs, including CUDC-427, a small molecule antagonist of IAP proteins, and CUDC-907, a dual PI3K and HDAC inhibitor. For more information, visit Curis' website at www.curis.com.



The Curis, Inc. logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=11347


CONTACT: For More Information:
Michael P. Gray
Chief Financial Officer
Curis, Inc.
617-503-6632
mgray@curis.com



Curis, Inc. Logo


Page: 1


Related Keywords: HEALTH, WEBCASTPro AV, Presentors, Business, Business Issues, Internet Media, Presentation, Events, webcast, Inc., Medicine, healthcare, Cancer, Surgery, Medication, Science, Financial, Medical, Cancer, Business,


DMO TEXT LINKS
(Click here to place a textlink on this site)

Vegas Pro 10 Available Now
Professional HD Video, audio, and Blu-Ray creation.
CLICK HERE!!!


@ Copyright, 2012 Digital Media Online, All Rights Reserved